

Title (en)  
PHARMACEUTICAL COMPOSITIONS COMPRISING DESGLY MIDODRINE AS AN ACTIVE DRUG SUBSTANCE

Title (de)  
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ENTHALTEND DESGLY MIDODRINE ALS WIRKSTOFF

Title (fr)  
COMPOSITIONS PHARMACEUTIQUES COMPRENANT DU DESGLY MIDODRINE EN TANT QUE SUBSTANCE MEDICAMENTEUSE ACTIVE

Publication  
**EP 1289493 A1 20030312 (EN)**

Application  
**EP 01933651 A 20010523**

Priority

- DK 0100362 W 20010523
- DK PA200000841 A 20000526
- DK 0100214 W 20010329
- US 82309301 A 20010329

Abstract (en)  
[origin: WO0189473A1] Novel pharmaceutical compositions comprising desglymidodrine or a pharmaceutically acceptable salt thereof as an active drug substance. Desglymidodrine is the active metabolite of the prodrug midodrine. The pharmaceutical composition may be presented in a suitable dosage form for oral, parenteral, mucosal, nasal, sublingual, buccal, topical, vaginal, rectal, ocular etc. administration. A pharmaceutical composition of the invention may be in the form of an immediate and/or modified release composition or it may be designed to release the active drug substance, desglymidodrine, in a relatively fast manner in order to enable a relatively fast onset of the therapeutical effect. The compositions have a suitable shelf-life, i.e. the desglymidodrine contained in the composition is not subject to a significant degradation under storage conditions normally acceptable for pharmaceuticals. Also disclosed is a method for treating animals such as, e.g. mammals and humans with a novel pharmaceutical composition comprising desglymidodrine. Furthermore, is disclosed a novel use of desglymidodrine in the treatment of septic shock and to a method for treating mammals (e.g. humans) suffering from septic shock with a sufficient amount of desglymidodrine.

IPC 1-7  
**A61K 31/165; A61K 9/20; A61K 9/28; A61K 9/54; A61K 9/127; A61K 9/08**

IPC 8 full level  
**A61K 9/00** (2006.01); **A61K 9/127** (2006.01); **A61K 9/20** (2006.01); **A61K 9/24** (2006.01); **A61K 9/28** (2006.01); **A61K 9/48** (2006.01); **A61K 9/50** (2006.01); **A61K 9/70** (2006.01); **A61K 31/137** (2006.01); **A61K 47/18** (2006.01)

CPC (source: EP)  
**A61K 9/0014** (2013.01); **A61K 9/0019** (2013.01); **A61K 9/0021** (2013.01); **A61K 9/0031** (2013.01); **A61K 9/0043** (2013.01); **A61K 9/0056** (2013.01); **A61K 9/0063** (2013.01); **A61K 9/0075** (2013.01); **A61K 9/0078** (2013.01); **A61K 9/008** (2013.01); **A61K 9/0095** (2013.01); **A61K 9/127** (2013.01); **A61K 9/2072** (2013.01); **A61K 9/209** (2013.01); **A61K 9/2886** (2013.01); **A61K 9/4808** (2013.01); **A61K 9/5073** (2013.01); **A61K 9/5078** (2013.01); **A61K 9/7084** (2013.01); **A61K 31/137** (2013.01); **A61K 47/18** (2013.01); **Y02A 50/30** (2017.12)

Citation (search report)  
See references of WO 0189473A1

Citation (examination)  
WO 0174334 A1 20011011 - NYCOMED DANMARK AS [DK], et al

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)  
**WO 0189473 A1 20011129**; AU 6008901 A 20011203; CA 2409950 A1 20011129; EP 1289493 A1 20030312

DOCDB simple family (application)  
**DK 0100362 W 20010523**; AU 6008901 A 20010523; CA 2409950 A 20010523; EP 01933651 A 20010523